


- **SUSPENDED** ALLIANCE A011104** Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer (**Feig**)
- UCI 15-83** Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting (**Tromberg**)
- UCI 10-39** Predicting Pathological Response within the First Week of Neoadjuvant Chemotherapy Using Functional Parameters Measured with Diffuse Optical Spectroscopic Imaging (DOSI) (**Tromberg**)
- UCI 11-15** Correlation of Clinical and MRI Findings with Prognosis of Breast Cancer Patients (**Su**)
- UCI 11-21** Analysis of Imaging Features of Breast Diseases and Breast Density Evaluated on Mammogram, Ultrasound & MRI Collected in a Database (**Su**)
- UCI 14-86** Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System (**Su**)
- UCI 14-85** Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System (**Su**)
- UCI 16-23** Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer [The WISDOM Study (Women Informed to Screen Depending On Measures of Risk)] (**Anton-Culver**)

SCREENING / DIAGNOSTIC / EPIDEMIOLOGIC / INTERVENTIONAL

BREAST CANCER

CORRELATIVE / OBSERVATIONAL

- UCI 95-29** Measurement of Breast Tissue Optical Properties (**Tromberg**)
- UCI 10-24** ATHENA Breast Health Network (**Anton-Culver**)
- UCI 12-10** Development of a Quantitative Tissue Optical Index of Breast Density for Prediction of Hormone Therapy Response (**O'Sullivan**)
- UCI 13-19** Registry Study of Patients Treated with Neoadjuvant Chemotherapy Followed by Mastectomy in Stage I, II, III BREAST CANCER (**Daroui**)
- UCI 14-25** Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (**Nelson**)
- UCI 14-62** Breast Tumor Oxygenation during Exercise (**Tromberg**)
- UCI 14-81** Mi Salud, Mi Vida: A Self-Discovery Tool for Latina Breast Cancer Survivors (**Sorkin**)
- **SUSPENDED** UCI 15-64** A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-Conserving Surgery (**Lin**)
- UCI 16-01** Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (**Nelson**)



Multiple Disease Sites

UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (**Ou**)

Stage I-III

UCI 14-67 A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (**Mehta**)

HER2- High Risk		Hormone+ High Risk	
<p>SWOG S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer (Mehta)</p>	<p>SWOG S1418 Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy (Mehta)</p>	<p>ALLIANCE A011502 A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial (Mehta)</p>	<p>NSABP B51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (Daroui)</p>

Advanced

UCI 17-45 COMPLEEMENT-1: An Open-Label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination with Letrozole for the Treatment of Men and Pre/Postmenopausal Women with Hormone Receptor-Positive (HR+) HER2-Negative (HER2-) Advanced Breast Cancer (aBC) with No Prior Hormonal Therapy for Advanced Disease (**Parajuli**)

Metastatic

Targeted therapy

ECOG EAY131 Molecular Analysis for Therapy Choice (MATCH) (**Bota**)

SWOG S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (**Bota**)

NRG BR002 A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (**Daroui**)

UCI 16-74 A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (**Carrillo**)

NSABP FB-10** A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer (**Parajuli**)

UCI 17-79** Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (**Parajuli**)



**BREAST
CANCER**